AVXL

Anavex Life Sciences Corporation
11.44
0.45 (4.09%)
Upgrade to Real-Time
Afterhours (Closed)
11.44
Volume 1,438,366
Bid Price 11.10
Ask Price 11.44
News (1)
Day High 11.71

Low
7.13

52 Week Range

High
15.24

Day Low 10.97
Company Name Stock Ticker Symbol Market Type
Anavex Life Sciences Corporation AVXL NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.45 4.09% 11.44 20:00:00
Open Price Low Price High Price Close Price Prev Close
11.09 10.97 11.71 11.37 10.99
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
12,467 1,438,366 $ 11.30 $ 16,253,851 - 7.13 - 15.24
Last Trade Time Type Quantity Stock Price Currency
19:39:48 49 $ 11.43 USD

Period:

Draw Mode:

Anavex Life Sciences Corporation Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 892.69M 78.03M 75.68M $ - $ - -0.62 -16.20
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - 13.00%

more financials information »

Anavex Life Sciences News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical AVXL Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week10.9111.719.8410.551,141,3490.534.86%
1 Month9.9111.719.4610.471,267,5851.5315.44%
3 Months12.3015.247.6310.502,552,007-0.86-6.99%
6 Months9.7715.247.6310.561,569,7901.6717.09%
1 Year11.6915.247.1310.521,276,900-0.25-2.14%
3 Years2.9831.502.2012.281,488,1208.46283.89%
5 Years2.6531.501.2510.801,065,3038.79331.7%

Anavex Life Sciences Description

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.